SCHEMBL16394402

SCHEMBL16394402

CC1(C)C(=O)Nc2cc(Nc3nc4c(-c5cnc6ccccc6c5)nccn4n3)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.56
EIF2AK4 Q9P2K8 1/20 0.56
JAK2 O60674 6/20 0.41
JAK3 P52333 4/20 0.41
PTK2 Q05397 3/20 0.41
LCK P06239 1/20 0.41
BRAF P15056 1/20 0.41
KDR P35968 1/20 0.41
MAPK14 Q16539 1/20 0.41
MARK3 P27448 1/20 0.36
KDM5B Q9UGL1 1/20 0.35
BRD4 O60885 2/20 0.34
CREBBP Q92793 2/20 0.34
ABL1 P00519 2/20 0.34
SRC P12931 1/20 0.34
JAK1 P23458 2/20 0.33
NR2F2 P24468 1/20 0.33
BUB1 O43683 1/20 0.33
PIK3CD O00329 1/20 0.33
PARP10 Q53GL7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210835 0.84 SYK (0.58) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15210732 0.84 SYK (0.56) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15210642 0.84 SYK (0.57) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15210757 0.84 SYK (0.78) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15212589 0.83 SYK (0.53) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL16394387 0.82 SYK (0.55) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15210947 0.82 SYK (0.59) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15210926 0.82 SYK (0.63) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15221139 0.82 SYK (0.53) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15212543 0.81 SYK (0.52) SYKEIF2AK4JAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK SYK 1/4885EIF2AK4 2/4885JAK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.